2016 N = 94 | 2017 N = 120 | 2018 N = 59 | 2019 N = 56 | 2020 N = 66 | Total N = 395 | Cochran-Armitage P-value | ||
---|---|---|---|---|---|---|---|---|
Age Group | Serogroup | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Under 1 | W | 2 (100.0) | 2 (100.0) | 3 (100.0) | 1 (100.0) | 0 (0.0) | 8 (100.0) | 0.99 |
1–4 | NG | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 1 (1.5) | 0.99 |
W | 21 (100.0) | 25 (100.0) | 6 (75.0) | 5 (100.0) | 1 (11.1) | 58 (85.3) | 0.99 | |
X | 0 (0.0) | 0 (0.0) | 2 (25.0) | 0 (0.0) | 7 (77.8) | 9 (13.2) | 1.00 | |
5–10 | C | 1 (4.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 0.19 |
NG | 0 (0.0) | 0 (0.0) | 2 (10.0) | 1 (6.7) | 1 (3.7) | 4 (3.1) | 0.98 | |
W | 22 (91.7) | 44 (97.8) | 10 (50.0) | 4 (26.7) | 2 (7.4) | 82 (62.6) | 0.81 | |
X | 1 (4.2) | 1 (2.2) | 8 (40.0) | 10 (66.7) | 24 (88.9) | 44 (33.6) | 1.00 | |
11–15 | B | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.3) | 0.99 |
NG | 0 (0.0) | 0 (0.0) | 1 (8.3) | 3 (23.1) | 0 (0.0) | 4 (5.1) | 1.00 | |
W | 16 (100.0) | 18 (94.7) | 7 (58.3) | 6 (46.2) | 3 (16.7) | 50 (64.1) | 0.97 | |
X | 0 (0.0) | 0 (0.0) | 4 (33.3) | 4 (30.8) | 15 (83.3) | 23 (29.5) | 0.97 | |
16–23 | B | 0 (0.0) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 0.57 |
C | 0 (0.0) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 0.42 | |
NG | 0 (0.0) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 1 (1.4) | 1.00 | |
W | 17 (100.0) | 20 (90.9) | 9 (69.2) | 7 (50.0) | 3 (37.5) | 56 (75.7) | 0.55 | |
X | 0 (0.0) | 1 (4.5) | 2 (15.4) | 7 (50.0) | 5 (62.5) | 15 (20.3) | 0.83 | |
24–44 | NG | 0 (0.0) | 0 (0.0) | 1 (50.0) | 1 (25.0) | 0 (0.0) | 2 (8.7) | 1.00 |
W | 9 (100.0) | 5 (100.0) | 1 (50.0) | 2 (50.0) | 1 (33.3) | 18 (78.3) | 1.00 | |
X | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 2 (66.7) | 3 (13.0) | 1.00 | |
45 + | W | 5 (100.0) | 2 (100.0) | 0 (0.0) | 3 (75.0) | 0 (0.0) | 10 (76.9) | 0.99 |
X | 0 (0.0) | 0 (0.0) | 1 (100.0) | 1 (25.0) | 1 (100.0) | 3 (23.1) | 1.00 |